CN1148181C - 黄酮木酯素在制备对子宫、卵巢和乳腺具有抗增殖活性的药物中的应用 - Google Patents

黄酮木酯素在制备对子宫、卵巢和乳腺具有抗增殖活性的药物中的应用 Download PDF

Info

Publication number
CN1148181C
CN1148181C CNB951978616A CN95197861A CN1148181C CN 1148181 C CN1148181 C CN 1148181C CN B951978616 A CNB951978616 A CN B951978616A CN 95197861 A CN95197861 A CN 95197861A CN 1148181 C CN1148181 C CN 1148181C
Authority
CN
China
Prior art keywords
silymarin
flavonolignan
cell
uterus
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB951978616A
Other languages
English (en)
Other versions
CN1185112A (zh
Inventor
E����ķ�͵���
E·波姆巴德利
P·莫拉佐尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Indena SpA
Original Assignee
Indena SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indena SpA filed Critical Indena SpA
Publication of CN1185112A publication Critical patent/CN1185112A/zh
Application granted granted Critical
Publication of CN1148181C publication Critical patent/CN1148181C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Abstract

本发明涉及黄酮木酯素如西利马林、水飞蓟素、水飞蓟宁、水飞蓟丁、其混合物、提取物和含有它们的制剂在治疗(和预防)子宫、卵巢和乳腺肿瘤中的应用。这些黄酮木酯素已被用于治疗各种病源引起的肝病，而且它们令人惊奇地对II型雌激素受体具有显著的亲和力，对子宫、卵巢和乳腺的肿瘤细胞系具有抗增殖活性。

Description

黄酮木酯素在制备对子宫、卵巢和乳腺具有 抗增殖活性的药物中的应用
本发明涉及黄酮木酯素(flavanolignane)单独或与已知的化疗药组合在制备用于治疗和预防子宫、卵巢和乳腺肿瘤的药物中的应用。
近来，已发现某些类黄酮具有抗肿瘤活性(Verna，癌症研究(CancerResearch)48，5754，1988)和对某些肿瘤具有化学预防活性(Cassady，天然产物杂志(J.Nat.Prod.)53，23，1990)。特别是槲皮黄酮-一种在植物中几乎普遍存在的类黄酮，已证明它除与常用的化疗药具有协同活性外，还对人白血病细胞的增殖具有一定的抑制活性(Larocca，英国血液学杂志(Br.J.of Haematology)75，489，1990)且对其它细胞系具有一定的抑制活性(Scambia，英国癌症杂志(Br.J.Cancer)62，942，1990-国际癌症杂志(Int.J.Cancer)46，1112，1990-癌症化疗药理学(Cancer Chemother.Pharmacol.)28，255，1991-妇科肿瘤学(Gynecologic Oncology)45，13，1992)。尽管还不知道这种增殖抑制作用的机理，但它似乎与这种类黄酮和II型雌激素受体的相互作用有关(Markaverich，类固醇生物化学杂志(J.Steroid Biochem.)30，71，1988)。最初由Clark(生物化学杂志(J.Biol.Chem.)253，7630，1978)描述的大鼠子宫中的这些受体与真正的雌激素受体(ER)不同，因为它们的存在浓度较高且对雌二醇的离解亲和常数(KD：10-20nM)低于雌激素受体的离解亲和常数(KD：0.2-1nM)。
现已令人惊奇地发现黄酮木酯素对II型雌激素受体具有高亲和力且对子宫、卵巢和乳腺中对顺铂和阿霉素具有抗药性的肿瘤细胞系具有非常显著的抗增殖活性，其中的西利马林已广泛用于治疗各种病源引起的肝病(hepatopathias)，它的三种主要组分已知为水飞蓟素、水飞蓟宁、水飞蓟丁和脱氢水飞蓟素且具有以下报道的结构：
Figure C9519786100041
水飞蓟素                                                 水飞蓟宁
                      水飞蓟丁为证明黄酮木酯素的抗增殖作用，已经在该化合物的存在下测定了来自各种人体肿瘤的不同稳定细胞系的生长曲线，并评价了它们与卵巢癌样品中的II型EBS相互作用的能力。
已经在卵巢肿瘤或其它器官肿瘤上进行了对雌激素受体结合的测定，这些肿瘤采用加有小牛血清和200单位/ml青霉素的Dulbecco改性培养基作为培养基以单层进行培养。用于试验的细胞每周进行胰蛋白酶酶化(trypsinated)并以8×10-4/ml的密度置于平板上，在含5％CO2的潮湿空气气氛中于37℃温育。为控制这些产品的抗增殖活性，将这些细胞以4×104/ml的浓度放入孔(Falcon 3046，Becton Dickinson NY)中。24小时后用新鲜培养基更换原培养基并加入溶于无水乙醇中的黄酮木酯素。在不存在活性成分下仅用载体以相同的试验条件处理对照组。在72小时的试验时间里，以24小时的时间间隔重复上述处理。将对照组的生长与处理样品的生长进行比较，通过直接计数细胞来评价对细胞增殖的抑制。
对于这些受体的剂量，将24小时后的细胞用标量的标记雌二醇(3H-E240Ci/mmol，Amershan UK)单独或在100倍用量的己烯雌酚存在下在4℃下温育2.5小时。
温育时间结束后，迅速用新鲜底物洗涤细胞，再用1M NaOH温育30分钟。用闪烁仪测量放射性并由含或不含己烯雌酚的制剂之间的不同来计算结合特异性。根据文献(Raneletti，1988)的常规方法，结果表达为每个细胞的结合位点数。
将对照组的生长与处理组的生长进行比较，通过直接计数细胞来评价对细胞增殖的抑制。
对不同细胞系的结果示于图1和表I及表V中。具体来说，图1示出了水飞蓟素对A2780 WT的抗增殖活性，A2780 WT是一种对ER呈阴性，对II型呈阳性的卵巢癌细胞系。
两组试验各重复三次，结果取其平均值。标准偏差低于10％。
该抗增殖活性是剂量依赖性的。表I所示的是浓度为0.01μM-20μM的水飞蓟素在细胞增殖中的有关数据；水飞蓟素对不同的细胞系表现出剂量依赖性抗增殖作用，包括那些对化疗药具有抗药性的细胞系(MCF-7ADRr，A2780 CIS)，其IC50为4.8-24μM。
表I：水飞蓟素对不同的稳定细胞系的抗增殖作用
细胞系      测试数*   细胞种类     暴露时间   IC50(μM)
A2780 WT     8         卵巢癌细胞    72h       12
A2780 CIS    5         卵巢癌细胞    72h       14
                       CIS抗性
OVCA-433     3         卵巢癌细胞    72h       4.8
MCF-7 ADRr   5         乳腺癌细胞    72h       24
                       ADR抗性
*各试验一式三份
为了进一步研究水飞蓟素的抗增殖活性，研究其对A2780 WT细胞周期的作用。如表II所示，细胞荧光分析表明水飞蓟素降低S相细胞的百分数，并使G0/G1相细胞的百分数稍微增加。
表II：水飞蓟素对A2780 WT在细胞周期不同相中的分布的作用
                      处理 *
              对照组       水飞蓟素(10μM)
G0/G1         58.7**      70.5
S             31           20.9
G2/M          10.3         8.6
*  A2780 WT细胞用或不用10μM水飞蓟素培养2天。
**  结果表达为细胞周期各相中的细胞百分数。
基于这些结果，试验水飞蓟素对某些化疗药，特别是顺铂(CIS)和阿霉素(ADR)的作用的增强。如表III所示，与单独使用相应剂量的药物相比，当水飞蓟素与CIS组合使用时，观察到对生长的协同抑制作用。
将水飞蓟素与ADR组合使用得到类似结果(表IV)。
为证明水飞蓟素与阿霉素或顺铂组合的这种作用是协同作用还是加合作用，用Berenbau(高级癌症研究(Adv.Cancer Res.)，25，269，1981)的isobolic方法分析数据。在亲本(A2780 WT，表III)和抗性(MCF 7，ADR r，表IV)细胞系中所得组合指数均低于1，从而证明两种药物的组合具有协同抗增殖活性。
表III：CIS-水飞蓟素组合对A2780 WT细胞系的协同抗增殖作用
CIS       水飞蓟素    ％       CIS      水飞蓟素  组合指数
(μg/ml)   (μM)      对照    (μg/ml)   (μM)
0.1        0.1        67       0.23      2.9       0.46
0.25       0.1        58       0.31      6.4       0.81
0.5        0.1        37       0.54      ＞50      ＜0.92
1          0.1        18       ＞1       ＞50      ＜1.00
0.1        1          54       0.34      8.2       0.41
0.25        1           35      0.56       ＞50     ＜0.46
0.5         1           25      0.82       ＞50     ＜0.62
1           1           12      ＞1        ＞50     ＜1.02
表IV：ADR与水飞蓟素组合对MCF-7 ADRr细胞系的协同抗增殖作用
ADR        水飞蓟素     ％      ADR        水飞蓟素   组合指数
(μg/ml)   (μM)        对照    (μM/ml)   (μM)
0.1         0.1         80      0.6         0.1       1.16
0.5         0.1         76      0.9         0.36      0.77
1           0.1         69      2.5         2.2       0.44
2.5         0.1         62      5.4         7         0.51
5           0.1         47      ＞10        35        ＜0.50
10          0.1         39      ＞10        ＞50      ＜1.00
不仅对稳定化的细胞系，而且对人肿瘤细胞原始培养物观察水飞蓟素及其类似物的抗增殖活性。各种被测试的黄酮木酯素具有类似的性能。在表V中，列出了水飞蓟素、水飞蓟宁、西利马林和脱氢水飞蓟素的有关数据。在这些试验中水飞蓟素和异水飞蓟素的非对映异构体形式也同样具有活性。表V：不同黄酮木酯素对A2780 WT细胞生长的作用化合物    试验数  暴露时间      IC50(μ M)水飞蓟素    8       72h            12脱氢水飞蓟素  3       72h            2.88水飞蓟宁    3       72h            12西利马林    3       72h            15
此外，通过按照文献的常用条件测量植入裸露的无胸腺小鼠中的肿瘤大小，证明上述黄酮木酯素可体内抑制细胞增殖。以1-100mg/Kg的剂量处理这些动物，发现被测试的肿瘤以高个体百分数明显消退，直到消失。已证明该产品对人卵巢、乳腺和子宫肿瘤的活性高于已知药物如它莫西芬。
水飞蓟宁、脱氢水飞蓟素和水飞蓟素的两种非对映异构体形式显示出特别显著的活性。在体外试验中，黄酮木酯素直接使用，而在体内试验中，使用其与磷脂的配合物，如EP-A-0209038中所述。
根据本发明，黄酮木酯素可经口或通过输注给药：对于经口给药，作为载体特别有用的是天然或合成磷脂，因为它们与所述化合物形成上述的脂溶性稳定配合物；以及含有中链脂肪酸甘油三酯的液体半合成甘油酯或能增进单一化合物、其天然混合物或含有它们的提取物的生物利用率的类似物。
对人来说，黄酮木酯素剂量为50-1500mg/天，主要通过口服给药。
本发明还涉及用于抗肿瘤治疗的组合物，含有组合形式的西利马林黄酮木酯素和抗肿瘤药，它们同时、依次或单独使用。
下列实施例进一步说明本发明。
                   实施例1
含有水飞蓟素与大豆卵磷脂的配合物的硬明胶胶囊：
组成：
水飞蓟素-大豆卵磷脂配合物          300mg
羧甲基纤维素钠                     16mg
滑石                               6mg
硬脂酸镁                           3mg
                   实施例2
含有脱氢水飞蓟素的软明胶胶囊：
组成：
脱氢水飞蓟素                       250mg
液体半合成甘油酯                   300mg
部分氢化的植物油                   49mg
大豆卵磷脂                         1mg
                   实施例3
含有西利马林与天然大豆磷脂的配合物的硬明胶胶囊：
组成：
西利马林-大豆磷脂配合物            360mg
羧甲基纤维素钠                     21mg
滑石                               6mg
硬脂酸镁                           3mg
                   实施例4
含有水飞蓟宁与大豆卵磷脂的配合物的硬明胶胶囊：
组成：
水飞蓟宁-大豆卵磷脂配合物          200mg
羧甲基纤维素钠                     10mg
滑石                               3mg
硬脂酸镁                           2mg

Claims (4)

1.黄酮木酯素在制备具有对II型雌激素受体拮抗活性和抗增殖活性的药物中的用途，该黄酮木酯素选自西利马林、水飞蓟素、水飞蓟宁、水飞蓟丁、脱氢水飞蓟素、其混合物或含有它们的提取物。
2.黄酮木酯素与磷脂的配合物在制备具有对II型雌激素受体拮抗活性和抗增殖活性的药物中的用途，该黄酮木酯素选自西利马林、水飞蓟素、水飞蓟宁、水飞蓟丁、脱氢水飞蓟素、其混合物或含有它们的提取物。
3.具有对II型雌激素受体拮抗活性和抗增殖活性的药物组合物，含有水飞蓟素作为活性成分，任意性地以与磷脂的配合物形式，与顺铂组合。
4.根据权利要求3的组合物，含有液体半合成中链脂肪酸甘油酯作为载体。
CNB951978616A 1995-05-23 1995-10-10 黄酮木酯素在制备对子宫、卵巢和乳腺具有抗增殖活性的药物中的应用 Expired - Fee Related CN1148181C (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT001047A/1995 1995-05-23
ITMI951047A IT1274549B (it) 1995-05-23 1995-05-23 Uso di flavanolignani per la preparazione di medicamenti ad attivita' antiproliferativa nei tumori dell'utero,dell'ovaio e del seno
ITMI95A001047 1995-05-23

Publications (2)

Publication Number Publication Date
CN1185112A CN1185112A (zh) 1998-06-17
CN1148181C true CN1148181C (zh) 2004-05-05

Family

ID=11371650

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB951978616A Expired - Fee Related CN1148181C (zh) 1995-05-23 1995-10-10 黄酮木酯素在制备对子宫、卵巢和乳腺具有抗增殖活性的药物中的应用

Country Status (21)

Country Link
US (2) US5912265A (zh)
EP (1) EP0828500B1 (zh)
JP (1) JP3178844B2 (zh)
KR (1) KR100290030B1 (zh)
CN (1) CN1148181C (zh)
AT (1) ATE268183T1 (zh)
AU (1) AU709802B2 (zh)
CA (1) CA2221753C (zh)
DE (1) DE69533112T2 (zh)
DK (1) DK0828500T3 (zh)
ES (1) ES2222466T3 (zh)
FI (1) FI119100B (zh)
HK (1) HK1006222A1 (zh)
HU (1) HU220627B1 (zh)
IT (1) IT1274549B (zh)
NO (1) NO317153B1 (zh)
PL (1) PL182064B1 (zh)
PT (1) PT828500E (zh)
RU (1) RU2161488C2 (zh)
SI (1) SI0828500T1 (zh)
WO (1) WO1996037209A1 (zh)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2432560A1 (fr) 1978-08-02 1980-02-29 Texas Instruments Inc Procede de decapage de metaux, en particulier d'aluminium, au plasma de tetrachlorure de silicium
US6379714B1 (en) 1995-04-14 2002-04-30 Pharmaprint, Inc. Pharmaceutical grade botanical drugs
EP1361210B1 (en) * 1996-08-12 2008-12-24 Celgene Corporation Novel immunotherapeutic agents and their use in the reduction of cytokine levels
US6239114B1 (en) * 1997-09-26 2001-05-29 Kgk Synergize Compositions and methods for treatment of neoplastic diseases with combinations of limonoids, flavonoids and tocotrienols
US6486193B2 (en) 1998-12-31 2002-11-26 Aventis Pharmaceuticals Inc. 3-substituted pyrrolidines useful as inhibitors of matrix metalloproteinases
WO2000066232A2 (fr) 1999-04-30 2000-11-09 Salomon S.A. Chassis articule
FR2792846B1 (fr) 1999-04-30 2001-07-27 Salomon Sa Patin a roues en ligne du type a platine superieure articulee
KR100342942B1 (ko) * 1999-07-05 2002-07-02 민경윤 카르두스 마리아누스 추출물 또는 이로부터 정제된 실리빈을함유하는 경구용 마이크로에멀젼 조성물
US20010025027A1 (en) * 2000-03-07 2001-09-27 Sonis Stephen T. Inhibition of ceramide for the prevention and treatment of oral mucositis induced by antineoplastic drugs or radiation
WO2002067853A2 (en) * 2000-10-06 2002-09-06 Probiochem, Llc A combination and method of treatment of hiv and viral diseases, vascular disease and cancer utilizing a cox-2 inhibitor and cystine
WO2002083124A1 (en) * 2000-10-06 2002-10-24 Probiochem, Llc A composition and method of sustaining chemotherapeutic effect while reducing dose of chemotherapeutic agent using cox-2 inhibitor and statin
WO2002064083A2 (en) * 2000-11-30 2002-08-22 The Children's Medical Center Corporation Synthesis of 3-amino-thalidomide and its enantiomers
US20040092565A1 (en) * 2001-07-25 2004-05-13 George Kindness Composition and method of sustaining chemotherapeutic effect while reducing dose of chemotherapeutic agent using cox-2 inhibitor and statin
EP1314438A1 (en) * 2001-11-23 2003-05-28 Nutricia N.V. Anti-proliferative composition
MXPA05003889A (es) * 2002-10-15 2005-06-22 Celgene Corp Farmacos inhibidores de citosina selectiva para tratar sindrome mielodisplastico.
US7776907B2 (en) * 2002-10-31 2010-08-17 Celgene Corporation Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
US20040091455A1 (en) * 2002-10-31 2004-05-13 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
KR20050061586A (ko) * 2002-10-31 2005-06-22 셀진 코포레이션 황반 변성의 치료를 위한 조성물
MXPA05004777A (es) * 2002-11-06 2005-07-22 Celgene Corp Metodos de uso y composiciones que comprenden farmacos inhibidores selectivos de citocina para el tratamiento y el manejo de padecimientos mieloproliferativos.
EP1581205A1 (en) * 2002-11-18 2005-10-05 Celgene Corporation Methods of using and compositions comprising (+)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
BR0316256A (pt) * 2002-11-18 2005-10-04 Celgene Corp Métodos de inibir a produção de tnf-alfa e a atividade de pde4, de tratar ou prevenir uma doença ou um distúrbio, de controlar os nìveis de camp em uma célula e de produzir um composto, composição farmacêutica e composto
CN100402023C (zh) * 2003-06-21 2008-07-16 山东绿叶天然药物研究开发有限公司 一种水飞蓟素软胶囊及其制备方法
US20080027113A1 (en) * 2003-09-23 2008-01-31 Zeldis Jerome B Methods of Using and Compositions Comprising Immunomodulatory Compounds for Treatment and Management of Macular Degeneration
KR100577514B1 (ko) * 2003-10-21 2006-05-10 한미약품 주식회사 비페닐디메틸디카복실레이트, 및 카르두스 마리아누스추출물 또는 이로부터 정제된 실리빈을 함유하는 경구용마이크로에멀젼 조성물
US20050142104A1 (en) * 2003-11-06 2005-06-30 Zeldis Jerome B. Methods of using and compositions comprising PDE4 modulators for the treatment and management of asbestos-related diseases and disorders
US20060084704A1 (en) * 2004-01-28 2006-04-20 Charles Shih Methods and compositions for enhancing degradation of nuclear receptor transcription factors and uses thereof
CA2554025A1 (en) * 2004-01-28 2005-08-11 Androscience Corporation Enhancement of anti-androgenic activity by a combination of inhibitors targeting different steps of a steroid-dependent gene activation pathway and uses thereof
CN1972686A (zh) * 2004-04-14 2007-05-30 细胞基因公司 选择性细胞因子抑制药在髓发育不良综合征中的用途
AU2005234783A1 (en) * 2004-04-23 2005-11-03 Celgene Corporation Methods of using and compositions comprising PDE4 modulators for the treatment and management of pulmonary hypertension
ZA200802490B (en) 2005-08-31 2009-10-28 Celgene Corp Isoindole-imide compounds and compositions comprising and methods of using the same
US8877780B2 (en) 2006-08-30 2014-11-04 Celgene Corporation 5-substituted isoindoline compounds
PL2428513T3 (pl) 2006-09-26 2017-10-31 Celgene Corp Pochodne 5-podstawionego chinazolinonu jako środki przeciwnowotworowe
RU2478635C2 (ru) 2006-10-19 2013-04-10 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Гетероарильные соединения, содержащие их композиции и способы лечения с применением этих соединений
US8710272B2 (en) 2007-01-08 2014-04-29 Androscience Corporation Compounds with (1 E, 6E)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disubstituted-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof
US8236852B2 (en) 2007-01-08 2012-08-07 Androscience Corporation Compounds with (substituted phenyl)-propenal moiety, their derivatives, biological activity, and use thereof
US9000222B2 (en) 2007-01-08 2015-04-07 Androscience Corporation Compounds with (1E, 6E)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disubstituted-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof
US7907654B2 (en) * 2007-04-27 2011-03-15 Hewlett-Packard Development Company, L.P. Laser diode with a grating layer
EP2175726A4 (en) 2007-07-31 2011-01-05 Androscience Corp COMPOSITIONS WITH ANDROGEN RECEPTOR DERIVATIVES AND METHOD FOR THE PROPHYLACTIC OR THERAPEUTIC TREATMENT OF SKIN DISEASES OR HAIR LOSS
EP2200999B1 (en) 2007-09-26 2014-08-13 Celgene Corporation 6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same
WO2009139880A1 (en) * 2008-05-13 2009-11-19 Celgene Corporation Thioxoisoindoline compounds and compositions and methods of using the same
CZ2008407A3 (cs) * 2008-06-26 2009-08-26 Agra Group, A. S. Vodorozpustný prípravek na bázi flavanonol lignanu a zpusob jeho prípravy
US8110578B2 (en) 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
KR20180000750A (ko) 2008-10-29 2018-01-03 셀진 코포레이션 암의 치료에 사용하기 위한 이소인돌린 화합물
WO2010093434A1 (en) 2009-02-11 2010-08-19 Celgene Corporation Isotopologues of lenalidomide
WO2010135396A2 (en) 2009-05-19 2010-11-25 Celgene Corporation Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
AU2010333767A1 (en) 2009-12-22 2012-07-05 Celgene Corporation (Methylsulfonyl) ethyl benzene isoindoline derivatives and their therapeutical uses
EP4289838A3 (en) 2010-02-11 2024-03-13 Celgene Corporation Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
US8603527B2 (en) 2010-10-25 2013-12-10 Signal Pharmaceuticals, Llc Pharmaceutical formulations of a substituted diaminopurine
US8853175B2 (en) 2011-01-10 2014-10-07 Celgene Corporation Phenethylsulfone isoindoline derivatives and their use
WO2012097116A2 (en) 2011-01-14 2012-07-19 Celgene Corporation Isotopologues of isoindole derivatives
CN106083812A (zh) 2011-03-11 2016-11-09 细胞基因公司 3‑(5‑氨基‑2‑甲基‑4‑氧‑4h‑喹唑啉‑3‑基)‑哌啶‑2,6‑二酮的固体形式及其药物组合物和用途
US20140221427A1 (en) 2011-06-22 2014-08-07 Celgene Corporation Isotopologues of pomalidomide
JP2014526508A (ja) 2011-09-14 2014-10-06 セルジーン コーポレイション シクロプロパンカルボン酸｛２−［（１ｓ）−１−（３−エトキシ−４−メトキシ−フェニル）−２−メタンスルホニル−エチル］−３−オキソ−２，３−ジヒドロ−１ｈ−イソインドール−４−イル｝−アミドの製剤
SI2797581T1 (sl) 2011-12-27 2020-08-31 Amgen (Europe) GmbH Formulacije (+)-2-(1-(3-etoksi-4-metoksi-fenil)-2-metansulfonil-etil)- 4-acetil aminoizoindolin-1,3-diona
SG11201500999WA (en) 2012-08-09 2015-04-29 Celgene Corp Salts and solid forms of (s)-3-(4-((4-morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and compositions comprising and methods of using the same
EP2752201A1 (en) * 2013-01-04 2014-07-09 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. C-terminal HSP90 inhibitors to treat pituitary adenomas
WO2014110558A1 (en) 2013-01-14 2014-07-17 Deuterx, Llc 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
EP2764866A1 (en) 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Inhibitors of nedd8-activating enzyme
US9132117B2 (en) 2013-06-17 2015-09-15 Kgk Synergize, Inc Compositions and methods for glycemic control of subjects with impaired fasting glucose
UA117141C2 (uk) 2013-10-08 2018-06-25 Селджин Корпорейшн Склади (s)-3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону
CN104714708B (zh) * 2013-12-11 2018-12-14 新益先创科技股份有限公司 控制点感测面板及其设计方法
TW201540323A (zh) 2014-01-15 2015-11-01 Celgene Corp ３－（５－胺基－２－甲基－４－側氧基－４ｈ－喹唑啉－３－基）－哌啶－２，６－二酮之調配物
US20170172921A1 (en) * 2016-12-14 2017-06-22 Mahmoud Reza Jaafari Polyphenolic compounds encapsualated in long circulating liposomes and use thereof
AU2019281613B2 (en) * 2018-06-09 2022-09-08 Jiangsu Atom Bioscience And Pharmaceutical Co., Ltd. Compound for treatment or prevention of liver diseases
CN109432084A (zh) * 2018-12-26 2019-03-08 温州医科大学 一种抗癌组合物及其在药物制备中的应用
CN112494479B (zh) * 2020-12-28 2022-06-21 华中科技大学同济医学院附属同济医院 茶黄素在制备卵巢功能保护药物方面的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2261434A (en) * 1991-11-15 1993-05-19 Inverni Della Beffa Spa New radical scavenging and antipoperoxidant flavanolignans their preparation and formulations for therapeutic use
CN1047944C (zh) * 1993-06-26 2000-01-05 曾庆通 一种治疗慢性肝炎的中药胶囊

Also Published As

Publication number Publication date
CA2221753C (en) 2001-07-24
WO1996037209A1 (en) 1996-11-28
AU3805195A (en) 1996-12-11
NO975334D0 (no) 1997-11-20
KR100290030B1 (ko) 2001-05-15
PL182064B1 (pl) 2001-10-31
JPH10511685A (ja) 1998-11-10
KR19990014941A (ko) 1999-02-25
JP3178844B2 (ja) 2001-06-25
HU220627B1 (hu) 2002-03-28
HK1006222A1 (en) 1999-02-19
HUT77966A (hu) 1998-12-28
NO975334L (no) 1997-11-20
NO317153B1 (no) 2004-08-30
ITMI951047A1 (it) 1996-11-23
PL323450A1 (en) 1998-03-30
IT1274549B (it) 1997-07-17
CA2221753A1 (en) 1996-11-28
ITMI951047A0 (it) 1995-05-23
DE69533112T2 (de) 2004-10-21
EP0828500B1 (en) 2004-06-02
ES2222466T3 (es) 2005-02-01
SI0828500T1 (en) 2004-10-31
DK0828500T3 (da) 2004-08-16
FI974268A0 (fi) 1997-11-18
FI974268A (fi) 1997-12-02
EP0828500A1 (en) 1998-03-18
US6218369B1 (en) 2001-04-17
AU709802B2 (en) 1999-09-09
DE69533112D1 (de) 2004-07-08
RU2161488C2 (ru) 2001-01-10
PT828500E (pt) 2004-08-31
CN1185112A (zh) 1998-06-17
ATE268183T1 (de) 2004-06-15
US5912265A (en) 1999-06-15
FI119100B (fi) 2008-07-31

Similar Documents

Publication Publication Date Title
CN1148181C (zh) 黄酮木酯素在制备对子宫、卵巢和乳腺具有抗增殖活性的药物中的应用
Saeed et al. Marine-derived drugs: Recent advances in cancer therapy and immune signaling
CN1277541C (zh) ATase抑制剂在制备使替莫唑胺对人癌细胞的毒性增效的药物组合物中的应用
CN1222294C (zh) 含吗啉蒽环类衍生物和抗癌剂的联合制剂
CN1306434A (zh) 用于预防和/或治疗骨质疏松症和因绝经综合征所致病变的组合物
CN1290504C (zh) 含有combretastatin和抗癌剂的复合药物
CN1267099C (zh) 对氧化毒性物质,特别是对心脏毒性物质具有保护作用的药物
CN1824317A (zh) 用于治疗肿瘤的含有鲨鱼软骨提取物和抗肿瘤剂的药物组合物
CN1429114A (zh) 联合化学疗法
CN1165509C (zh) 紫草萘醌类衍生物及其在制备抗癌药物中的应用
CN1302780C (zh) 烷基胆碱磷酸在制备用抗肿瘤药之前和/或期间治疗肿瘤的药物中的应用
CN1897949A (zh) 包含使用et－743和紫杉醇来治疗癌症的联合疗法
CN101057913A (zh) 牡荆属医药新用途及药物中间体的制备方法
CN1217669C (zh) 柚皮苷用于制备治疗咳嗽的药物
CN1679539A (zh) 抗肿瘤的协同药物组合物
CN1245407C (zh) 藤黄酸类化合物的复合物,其制备方法和以该复合物为活性成份的药物组合物
CN1289506C (zh) 藤黄酸类化合物的复合物,其制备方法及以该复合物为活性成份的药物组合物
CN1056082C (zh) 一种抗癌药
CN1853625A (zh) 木犀草素与一种铂类化疗药物的联合
RU2192861C1 (ru) Композиция для антибластической терапии
CN1037575C (zh) 8-氯腺苷制备抗肿瘤药物
RU2694373C2 (ru) Способ лечения кастрационно-устойчивого рака простаты
CN1679604A (zh) 抗肿瘤的协同药物组合物
CN1682741A (zh) 一种抗肿瘤药物23－羟基白桦酸脂肪乳剂及其制备方法
CN1879615A (zh) 抗肿瘤的协同药物组合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20040505

Termination date: 20111010